Quidel: Mixed Sentiment Persists Amid Uncertainty in QuidelOrtho's Core Profitability: Analyst

QuidelOrtho Corporation (NASDAQ: QDEL) released preliminary Q3 revenue of $738 million to $744 million, primarily driven by higher respiratory product sales, particularly SARS and flu. The company says earlier-than-expected demand for respiratory products in core markets drives strong preliminary performance. The company sees non-respiratory product revenue of $557 million-$560 million and respiratory product revenue of $181 million-$184 million. William Blair says respiratory product revenue is well above their estimate of $101 million. The upside here comes as little surprise given management's intra-quarter bullish tone on respiratory (COVID) testing demand from retail and point-of-care settings; however, the magnitude of ...Full story available on Benzinga.com